Achieving Appropriate Access for the Treatment of Atopic Dermatitis:
Medical and Pharmacy Management Strategies for Managed Care and Payer Professionals Infographic

Expert Faculty Author:

Peter Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director
Chicago Integrative Eczema Center
Click here for biography

Edmund Pezalla, MD, PhD, MPH
CEO
Enlightenment Bioconsult, LLC
Click here for biography

Terry Richardson, PharmD, BCACP
Vice President, Education Strategy and Development
Impact Education, LLC
Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

Statement of Need/Program Overview
Novel treatments and management strategies have the potential to target the underlying pathology resulting in decreased clinical and economic burden for the patient and health care system. However, managed care pharmacists and other payer professionals can lack knowledge of the clinical, economic, and humanistic burden of atopic dermatitis (AD) which can empower them to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes.

Educational Objectives
After completing this activity, the participant should be better able to:

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, the National Eczema Association and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hours.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.25 contact hours (0.025 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-363-H01-P
This activity is certified as Knowledge-based CPE.

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Name of Faculty or Presenter

Reported Financial Relationship

Peter Lio, MD Grant/Research Support: AOBiome, Regeneron/Sanofi Genzyme, and AbbVie
Speakers Bureau/Honoraria for non-CME: Regeneron/Sanofi Genzyme, Pfizer, AbbVie, Eli Lilly, LEO, Galderma, Incyte, and L'Oreal
Consultant/Advisory Board: Almirall, ASLAN Pharmaceuticals, Concerto Biosciences, Dermavant, Regeneron/Sanofi Genzyme, Pfizer, LEO Pharmaceuticals, Dermira, AbbVie, Eli Lilly, Micreos, Lipidor, L'Oreal, Pierre-Fabre, Johnson & Johnson, Janssen, Castle Biosciences, Level Ex, Boston Skin Science (KPAway), Unilever, Menlo Therapeutics, Theraplex, Kaleido Biosciences, IntraDerm, AOBiome, Lipidor, Realm Therapeutics, Altus Labs, Galderma, Verrica, Arbonne, Amyris, Bodewell, YobeeCare, Burt's Bees, SkinFix, Sibel Health, Sonica LLC, My-Or Diagnostics, and Kimberly-Clark.
Edmund Pezalla, MD, PhD, MPH Edmund Pezalla, MD, PhD, MPH has nothing to disclose.
Terry Richardson, PharmD, BCACP Terry Richardson, PharmD, BCACP has nothing to disclose.

The PIM, NEA and Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.